Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Junker

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Annals of the Rheumatic Diseases|October 23, 2015
Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)K Hørslev-Petersen, M L Hetland, L M Ørnbjerg, et al.
Scandinavian Journal of Rheumatology|September 11, 2014
Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritisA Krol, P Garred, N H H Heegaard, et al.
Scandinavian Journal of Rheumatology|August 29, 2013
Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progressionT Ellingsen, I Hansen, J Thorsen, et al.
The Pharmacogenomics Journal|May 6, 2015
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritisS B Krintel, C Dehlendorff, M L Hetland, et al.
Annals of the Rheumatic Diseases|April 5, 2008
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)M L Hetland, B Ejbjerg, K Hørslev-Petersen, et al.
Annals of the Rheumatic Diseases|May 11, 2013
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trialT W Jensen, M S Hansen, K Hørslev-Petersen, et al.
Scandinavian Journal of Rheumatology|July 10, 2018
Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trialC H Brahe, M Østergaard, J S Johansen, et al.
Scandinavian Journal of Rheumatology|November 4, 2016
Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)S Møller-Bisgaard, B J Ejbjerg, I Eshed, et al.
Development (Cambridge, England)|April 19, 2012
Identification of molecular compartments and genetic circuitry in the developing mammalian kidneyJing Yu, M Todd Valerius, Mary Duah, et al.
Clinical Rheumatology|December 7, 2016
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trialL M Ørnbjerg, M Østergaard, T Jensen, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Annals of the Rheumatic Diseases|October 23, 2015
Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)K Hørslev-Petersen, M L Hetland, L M Ørnbjerg, et al.
Scandinavian Journal of Rheumatology|September 11, 2014
Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritisA Krol, P Garred, N H H Heegaard, et al.
Scandinavian Journal of Rheumatology|August 29, 2013
Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progressionT Ellingsen, I Hansen, J Thorsen, et al.
The Pharmacogenomics Journal|May 6, 2015
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritisS B Krintel, C Dehlendorff, M L Hetland, et al.
Annals of the Rheumatic Diseases|April 5, 2008
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)M L Hetland, B Ejbjerg, K Hørslev-Petersen, et al.
Annals of the Rheumatic Diseases|May 11, 2013
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trialT W Jensen, M S Hansen, K Hørslev-Petersen, et al.
Scandinavian Journal of Rheumatology|July 10, 2018
Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trialC H Brahe, M Østergaard, J S Johansen, et al.
Scandinavian Journal of Rheumatology|November 4, 2016
Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)S Møller-Bisgaard, B J Ejbjerg, I Eshed, et al.
Development (Cambridge, England)|April 19, 2012
Identification of molecular compartments and genetic circuitry in the developing mammalian kidneyJing Yu, M Todd Valerius, Mary Duah, et al.
Clinical Rheumatology|December 7, 2016
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trialL M Ørnbjerg, M Østergaard, T Jensen, et al.
Pageof 14